Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | MGMT | P16455 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17813819 | 0.81 | ALDH1A1 (0.34) | MEN1KMT2AALDH1A1MAPTCYP2D6 | |
| SCHEMBL17808317 | 0.80 | — | — | |
| SCHEMBL17813866 | 0.73 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL26496256 | 0.68 | CYP2D6 (0.31) | CDK1CDK2CYP2D6 | |
| SCHEMBL28985011 | 0.66 | KDM4E (0.51) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL6232310 | 0.66 | ALDH1A1 (0.49) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL12896014 | 0.64 | LMNA (0.32) | — | |
| SCHEMBL12765876 | 0.64 | LMNA (0.41) | KMT2AKDM4EALDH1A1MAPTCYP2D6 | |
| SCHEMBL11420950 | 0.64 | MAPT (0.32) | KDM4EALDH1A1MAPTCA12CA9 | |
| SCHEMBL18699147 | 0.63 | ELANE (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611248-B2 | Chemical compounds | SYNGENTA LIMITED (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160159767-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159767-A1 | CHEMICAL COMPOUNDS | DDT, CBR3, CYP1B1 | MEN1 2767/4885KMT2A 1627/4885KDM4E 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.